Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer

Journal of Oncology Practice

Volumn 11, Issue 2, 2015, Pages 126-132

  Enright, Katherine ^a,b,c,d   Grunfeld, Eva ^a,b,c,d   Yun, Lingsong ^a,b,c,d   Moineddin, Rahim ^a,b,c,d   Ghannam, Mohammad ^a,b,c,d   Dent, Susan ^a,b,c,d   Eisen, Andrea ^a,b,c,d   Trudeau, Maureen ^a,b,c,d   Kaizer, Leonard ^a,b,c,d   Earle, Craig ^a,b,c,d   Krzyzanowska, Monika K ^a,b,c,d  

^a CREDIT VALLEY HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; EPIRUBICIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER PATIENT; COMORBIDITY; CONTROLLED STUDY; EARLY CANCER; EMERGENCY WARD; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HEALTH CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; EMERGENCY HEALTH SERVICE; MIDDLE AGED; ONTARIO; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MIDDLE AGED; ONTARIO; PACLITAXEL; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84925329080     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.001073     Document Type: Article

References (34)

1. Reference deleted
2. American Cancer Society: Cancer Facts and Figures 2014. www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. Peppercorn JM, Weeks JC, Cook EF, et al: Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 363:263-270, 2004
5. Vist GE, Hagen KB, Devereaux PJ, et al: Systematic review to determine whether participation in a trial influences outcome. BMJ 330:1175, 2005
6. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008, 2001
7. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
8. Du XL, Osborne C, Goodwin JS: Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642, 2002
9. Robles SC, Marrett LD, Clarke EA, et al: An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41:495-501, 1988
10. Clarke EA, Marrett LD, Kreiger N: Cancer registration in Ontario: A computer approach. IARC Sci Publ 95:246-257, 1991
11. Richards J, Brown A, Homan C: The data quality of study of the Canadian Discharge Abstract Database. Presented at the Statistics Canada Symposium, Ottawa, Ontario, Canada, October 17-19, 2001
12. Canadian Institute for Health Information: Data Quality Study of Ontario Emergency Department Visits for 2004-2005. https://secure.cihi.ca/free-products/vol1-nacrs-executive-summary-nov2-2007.pdf
13. Madarnas Y, Dent SF, Husain SF, et al: Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres. Curr Oncol 18:119-125, 2011
14. Vandenberg T, Younus J, Al-Khayyat S: Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: Discrepancy between published reports and community practice-A retrospective analysis. Curr Oncol 17:2-3, 2010
15. Altwairgi AK, Hopman WM, Mates M: Real-world impact of granulocytecolony stimulating factor on febrile neutropenia. Curr Oncol 20:e171-e179, 2013
16. Krzyzanowska MK, Enright K, Moineddin R, et al: Can we accurately identify chemotherapy-related acute care visits in administrative data? J Clin Oncol 32, 2014 (suppl 30; abstr 185)
17. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
18. Statistics Canada: Low income cut-offs. www.statcan.gc.ca/pub/75f0002m/2012002/lico-sfr-eng.htm
19. Jones S, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
20. Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006
21. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 291:2720-2726, 2004
22. Aapro MS, Köhne CH, Cohen HJ, et al: Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 10:198-204, 2005
23. Antman K, Amato D, Wood W, et al: Selection bias in clinical trials. J Clin Oncol 3:1142-1147, 1985
24. Simon MS, Du W, Flaherty L, et al: Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046-2052, 2004
25. Gross CP, Filardo G, Mayne ST, et al: The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer 103:483-491, 2005
26. Garg P, Rana F, Gupta R, et al: Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Breast J 15:404-408, 2009
27. Zauderer M, Patil S, Hurria A: Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 117:205-210, 2009
28. Stiller CA: Centralised treatment, entry to trials and survival. Br J Cancer 70:352-362, 1994
29. Braunholtz DA, Edwards SJ, Lilford RJ: Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 54:217-224, 2001
30. Barcenas CH, Niu J, Zhang N, et al: Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 32:2010-2017, 2014
31. Hassett MJ, Rao SR, Brozovic S, et al: Chemotherapy-related hospitalization among community cancer center patients. Oncologist 16:378-387, 2011
32. Coriat R, Boudou-Rouquette P, Durand JP, et al: Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy. J Oncol Pract 8:205-210, 2012
33. Kearney N, McCann L, Norrie J, et al: Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Support Care Cancer 17:437-444, 2009
34. Maguire R, McCann L, Miller M, et al: Nurse's perceptions and experiences of using of a mobile-phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy-related toxicity. Eur J Oncol Nurs 12:380-386, 2008